Alexey L. Margolin graduated from Moscow University in 1975 with an M.S. in chemistry. In 1979 he received his doctorate in bioorganic chemistry from the same university. He then continued his research work at the Belozersky Laboratory of Molecular Biology and Bioorganic Chemistry. In 1986 he moved to the Massachusetts Institute of Technology where he worked on enzyme-catalyzed reactions in organic solvents with Professor Alexander Klibanov. From 1988 to 1993 Dr. Margolin was responsible for biocatalysis activities at the Merrell Dow Research Institute. He then moved to Altus Biologics where he spearheaded the research and development of cross-linked enzyme crystals. He is currently Vice President of Science at Altus Biologics and is responsible for all science activities conducted by the company. Dr. Margolins research interests focus on the field of biocatalysis, the use of enzymes in organic synthesis, and protein stabilization and immobilization. His recent efforts include the development of protein crystals for manufacture, formulation, and delivery of biopharmaceuticals. Manuel A. Navia, born in Havana, Cuba, received his B.A. in physics from New York University in 1967 and his M.S. in biophysics from the University of Chicago in 1969, after which his studies were interrupted by military service. He received his Ph.D. in biophysics in 1974 from the University of Chicago, where he worked with Prof. Paul Sigler on the structure of tRNA. Postdoctoral studies with Dr. David Davies on the structures of an intact antibody and antibody fragments followed at the National Institutes of Health in Bethesda, Maryland. From 1980 to 1989, Dr. Navia worked at Merck Research Laboratories, where he engaged in the structure-based drug design of enzyme inhibitors that resulted in approved and marketed drugs. From 1989 to 1997, he was at Vertex Pharmaceuticals in Cambridge, Massachusetts, where he solved the structures of calcineurin, the IL-1 beta converting enzyme (Caspase-1), and the HIV protease, in support of structure-based drug design programs against immunosuppression, inflammation, and HIV infection. The latter program led to discovery and development of amprenavir, now approved for the control of AIDS. While at Vertex, Dr. Navia was a co-inventor of the CLEC technology and founder of what is now Altus Biologics. In 1997, he cofounded The Althexis Company, in Waltham, Massachusetts, where he serves as Executive Vice President. Althexis is dedicated to the structure-based drug design of novel antibiotics.